The farnesyl transferase inhibitor SCH 66336 induces a G2→ M or G1 pause in sensitive human tumor cell lines

Experimental Cell Research

Volumn 262, Issue 1, 2001, Pages 17-27

  Ashar, Hena R ^a   James, Linda ^a   Gray, Kimberly ^a   Carr, Donna ^a   McGuirk, Marnie ^a   Maxwell, Eugene ^a   Black, Stuart ^a   Armstrong, Lydia ^a   Doll, Ronald J ^b   Taveras, Arthur G ^b   Bishop, W Robert ^a   Kirschmeier, Paul ^a  

^a Department of Tumor Biology ^*  (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cell cycle; FTI; Mitotic pause; P53; Ras

Indexed keywords

LONAFARNIB; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P53; RAS PROTEIN; SCH 66177; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; GENOTYPE; HUMAN; HUMAN CELL; IC 50; MITOSIS INHIBITION; MUTATION; PRIORITY JOURNAL; TUMOR CELL LINE;

EID: 0034776102     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.2000.5076     Document Type: Article

References (39)

1. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity
2. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic
3. Protein prenylation: More than just glue?
4. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB
5. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics
6. Benzodiazepine peptidomimetics: Potent inhibitors of Ras farnesylation in animal cells
7. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor
8. Peptidomimetic inhibitors of Ras farnesylation and function in whole cells
9. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice
10. Ras oncogenes in human cancer: A review
11. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956
12. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines
13. Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells
14. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors
15. Structure-activity relationship of 3-substituted N-(pyridinylacetyl)-4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b] pyridin-11-ylidene)-piperidine inhibitors of farnesyl-protein transferase: Design and synthesis of in vivo active antitumor compounds
16. Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo
17. Characterization of Ha-ras, N-ras, KiRas4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I
18. I block in p53 wild type tumor cells
19. Lack of correlation between natural killer activity and tumor growth control in nude mice with different immune defects
20. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
21. (+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2- b]-pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamide (SCH-66336): A very potent farnesyl protein transferase inhibitor as a novel antitumor agent
22. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis
23. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic ras signaling by inducing cytoplasmic accumulation of inactive Ras-raf complexes
24. Specific isoprenoid modification is required for function of normal, but not oncogenic, Ras protein
25. The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic ras signaling and transformation
26. Farnesyltransferase inhibitors and cancer treatment: Targeting simply Ras?
27. Proteolytic cleavage of human p53 by calpain: A potential regulator of protein stability
28. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F, and alter the association of CENP-E with the microtubules
29. GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells
30. Requirement for p53 and p21 to sustain G2 arrest after DNA damage
31. GADD45 induction of a G2/M cell cycle checkpoint
32. The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner
33. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis
34. Apoptosis and the cell cycle
35. Apoptosis and the cell cycle
36. p53 involvement in control of G2 exit of the cell cycle: Role in DNA damage-induced apoptosis
37. Prenylation of RhoB is required for its cell transforming function but not its ability to activate serum response element-dependent transcription
38. Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment
39. Non-Ras targets of farnesyltransferase inhibitors: Focus on Rho